PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

This study has been completed.
Information provided by Millennium Pharmaceuticals

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Multiple Myeloma
2		Additional conditions recognized in this trial
			Neoplasms, Plasma Cell
3		More general conditions related to this trial
			Blood Protein Disorders
			Cardiovascular Diseases
			Hematologic Diseases
			Hemorrhagic Disorders
			Hemostatic Disorders
			Immune System Diseases
			Immunoproliferative Disorders
			Lymphoproliferative Disorders
			Neoplasms
			Neoplasms by Histologic Type
			Paraproteinemias
			Vascular Diseases
4		Interventions listed in this trial
			bortezomib
5		Additional drug interventions recognized in this trial
			Dexamethasone
6		More general drug interventions related to this trial
			Anti-Inflammatory Agents
			Antiemetics
			Antineoplastic Agents
			Antineoplastic Agents, Hormonal
			Autonomic Agents
			Central Nervous System Agents
			Enzyme Inhibitors
			Gastrointestinal Agents
			Glucocorticoids
			Hormones
			Hormones, Hormone Substitutes, and Hormone Antagonists
			Molecular Mechanisms of Pharmacological Action
			Peripheral Nervous System Agents
			Pharmacologic Actions
			Physiological Effects of Drugs
			Protease Inhibitors
			Therapeutic Uses
7		Sponsors listed in this trial
			Millennium Pharmaceuticals